Phenobarbital

GATA binding protein 3 ; Homo sapiens







15 Article(s)
Download
PMID
Title
Pub. Year
#Total Relationships
1 34808009 Prognostic impact of Schlafen 11 in bladder cancer patients treated with platinum-based chemotherapy. 2022 Feb 1
2 35021081 2-Hydroxyglutarate destabilizes chromatin regulatory landscape and lineage fidelity to promote cellular heterogeneity. 2022 Jan 11 1
3 33382535 Chromosome 2q gain and epigenetic silencing of GATA3 in microglandular adenosis of the breast. 2021 May 1
4 33858483 Subtype-associated epigenomic landscape and 3D genome structure in bladder cancer. 2021 Apr 15 2
5 33909826 Combined use of immunohistochemical markers of basal and luminal subtypes in urothelial carcinoma of the bladder: Association with clinicopathological features and outcomes. 2021 1
6 34057115 Gata-3 and KI-67 expression in correlation with molecular subtypes of breast cancer. 2021 2
7 34108177 Heterogeneity in NECTIN4 Expression Across Molecular Subtypes of Urothelial Cancer Mediates Sensitivity to Enfortumab Vedotin. 2021 Sep 15 1
8 34117603 Co-expression of transcription factor AP-2beta (TFAP2B) and GATA3 in human mammary epithelial cells with intense, apicobasal immunoreactivity for CK8/18. 2021 Dec 1
9 34358678 Transcriptome Analysis Identifies GATA3-AS1 as a Long Noncoding RNA Associated with Resistance to Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer Patients. 2021 Oct 1
10 34517157 Gene expression analysis of invasive breast carcinoma yields differential patterns in luminal subtypes of breast cancer. 2021 Dec 3
11 34561764 Reduced menin expression leads to decreased ERα expression and is correlated with the occurrence of human luminal B-like and ER-negative breast cancer subtypes. 2021 Dec 1
12 34725332 ARSD, a novel ERα downstream target gene, inhibits proliferation and migration of breast cancer cells via activating Hippo/YAP pathway. 2021 Nov 2 1
13 32429656 Differences in GATA3 expression among histological/molecular subtypes and grades in infiltrating breast carcinoma (IBC) are important in the diagnosis of metastatic breast carcinoma. 2020 1
14 32546765 Assessment of Luminal and Basal Phenotypes in Bladder Cancer. 2020 Jun 16 1
15 31376015 C1orf106, an innate immunity activator, is amplified in breast cancer and is required for basal-like/luminal progenitor fate decision. 2019 Sep 1